Edition:
India

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

14.63USD
13 Dec 2017
Change (% chg)

$-0.16 (-1.08%)
Prev Close
$14.79
Open
$14.80
Day's High
$14.96
Day's Low
$14.51
Volume
2,013
Avg. Vol
5,852
52-wk High
$33.48
52-wk Low
$13.33

Summary

Name Age Since Current Position

Mark Iwicki

50 Chairman of the Supervisory Board

Ton Logtenberg

Chief Executive Officer

John Crowley

41 2016 Chief Financial Officer, Executive Vice President

Shelley Margetson

2016 Chief Operating Officer, Executive Vice President

John de Kruif

Chief Technology Officer

Saterah Shamsili

Chief Marketing Officer

Mark Throsby

Chief Scientific Officer

Lex Bakker

Chief Development Officer

Ellen Broug

2010 Secretary to the Supervisory Board

Wolfgang Berthold

61 2010 Member of the Supervisory Board

Lionel Carnot

49 2010 Member of the Supervisory Board

Gabriele Dallmann

2011 Member of the Supervisory Board

John de Koning

2010 Member of the Supervisory Board

Florent Gros

2010 Member of the Supervisory Board

Elaine Jones

59 2010 Member of the Supervisory Board

Mark Krul

2010 Member of the Supervisory Board

Biographies

Name Description

Mark Iwicki

Mr. Mark Iwicki is Chairman of the Supervisory Board of Merus BV. He graduated from Ball State University with a BA degree in Business Administration and from Loyola University with an MBA degree. He has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization across a broad range of therapeutic areas. Most recently, Mr. Iwicki served as CEO of Civitas Therapeutics, which was sold to Acorda Therapeutics in 2014. Prior to joining Civitas, he was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He also served as President and CEO of Sunovion Pharmaceuticals, where he provided leadership for the successful launch of that company, which was created following the acquisition of Sepracor by Dainippon Sumitomo Pharmaceuticals. Mr. Iwicki also previously held key senior leadership roles with Sepracor and Novartis Pharmaceuticals. He currently also sits on the Board of Directors for Kala Pharmaceuticals, Allergen Research Corporation, Nimbus Therapeutics and Taris Biomedical.

Ton Logtenberg

Mr. Ton Logtenberg is Chief Executive Officer of Merus BV. He holds a Ph.D. in Medical Biology. He was a professor at the Department of Immunology in Utrecht, The Netherlands and a co-founder of the Dutch biotechnology company Crucell NV, serving the company as Executive Vice President and Chief Scientific Officer.

John Crowley

Mr. John J. Crowley, CPA, serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Crowley has over 20 years of global biotechnology financial and operational experience. Most recently, he served as Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer of Charles River Laboratories. Previously, he served as the Vice President, Corporate Controller and Chief Accounting Officer at Ironwood Pharmaceuticals and held senior corporate finance positions at Vertex Pharmaceuticals and Sunovian Pharmaceuticals, Inc. Mr. Crowley is a Certified Public Accountant and graduated Summa Cum Laude from Babson College with B.S. degrees in both Economics and Accountancy.

Shelley Margetson

Ms. Shelley Margetson serves as Chief Operating Officer, Executive Vice President of the Company. She was Chief Financial Officer of Merus BV. She is an Associate of the Chartered Institute of Management Accountants. Prior to joining Merus, she was Vice President Finance of PanGenetics B.V., a therapeutic antibody development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. Shelley has worked in the biotechnology industry since 2001 for companies located in the UK, France and The Netherlands.

John de Kruif

Mr. John de Kruif serves as Chief Technology Officer at Merus B.V. Mr. de Kruif holds a Ph.D. in Biology and spent his scientific career on phage display and engineering of human antibodies. Before joining Merus, He was Director Antibody Research and Development at biotechnology company Crucell NV.

Saterah Shamsili

Ms. Saterah Shamsili is Chief Marketing Officer of Merus BV. She has more than 22 years of experience in general medicine, internal medicine and medical oncology. For the past 13 years, she has focused on both translational and clinical cancer research. She has more than eight years of experience in the pharmaceutical industry, including drug development, R&D, medical affairs, drug safety and pharmacovigilance and holds a PhD in Neuro-Oncology from Erasmus University Rotterdam. Prior to joining Merus, Setareh van Driel Shamsili was Global Medical Leader Oncology at Astellas Pharma Global Development.

Mark Throsby

Mr. Mark Throsby serves as Chief Scientific Officer of Merus BV. He holds a Ph.D. in Immunology. Before joining Merus, he was Director Antibody Discovery at Dutch biotechnology company Crucell were he was responsible for initiation of projects in viral and bacterial diseases leading to clinical development programs and licensing deals.

Lex Bakker

Mr. Lex Bakker serves as Chief Development Officer of Merus BV. He holds a Ph.D. in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute (Palo Alto, CA). Prior to joining Merus, he worked at biotechnology company Crucell where he directed the preclinical and clinical development of a human antibody combination for rabies post-exposure prophylaxis.

Ellen Broug

Ms. Ellen Broug is Secretary to the Supervisory Board of Merus BV. Before joining Merus, she was Director of Alliance Management at PanGenetics B.V. and has held various positions within the Dutch biotechnology arena, including Associate Director at ABN AMRO Capital Life Sciences (now Forbion Capital Partners), Head Scientific Documentation & Target Evaluation at Genmab and Head of IP at Agamyxis (Hubrecht Institute).

Wolfgang Berthold

Mr. Wolfgang Berthold is Member of the Supervisory Board of Merus BV. He graduated from University of London with a PhD in Biochemistry. He has been a member of the Board since 2010. Wolf is the president of Berthold BioPharm Consulting GmbH, Switzerland. For more than 30 years, he has held senior positions at Boehringer Ingelheim, D, Roche, NJ, USA, IDEC, CA, USA, and BiogenIdec, CH, being responsible for various aspects in the CMC area of Manufacturing Operations, Process Development and Facilities & Engineering. Until recently, he was Chief Technology Officer and Board Director at BiogenIdec International, CH.

Lionel Carnot

Mr. Lionel Carnot is Member of the Supervisory Board of Merus BV. He graduated from INSEAD with an MBA degree and from University of Geneva with an MSc degree in Molecular Biology. He has been a member of the Board since January 2010. He is an Investment Partner at Bay City Capital and has been extensively involved in the firm’s activities since he joined The Pritzker Organization in 2000. Prior to The Pritzker Organization, he was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, and was a strategy and management consultant to the biopharmaceutical industry while at Booz Allen & Hamilton and Accenture Strategic Services.

Gabriele Dallmann

Dr. Gabriele Dallman is Member of the Supervisory Board of Merus BV. He has been a member of the Board since 2011.?He is the founder of Biopharma Excellence, EUCRAF and Pharmatching.com. Dr. Dallmann has over 25 years of experience in facilitating drug development and is an expert in the field of Regulatory Affairs. Dr. Dallmann is an ex-regulator who worked at Committees of the European Medicines Agency (EMA) and at the Paul-Ehrlich-Institut, Germany’s federal agency for Vaccines and Biomedicines. Dr. Dallmann is biologist by training with a PhD in immunology from Berlin University (Charite).

John de Koning

Mr. John de Koning is Member of the Supervisory Board of Merus BV. He graduated from Erasmus University with a PhD degree and from Utrecht University with a Masters degree in Molecular Biology. He has been a member of Merus´ Board since January 2010. He is a partner at Life Sciences Partners (LSP). He was Managing Director of Semaia Pharmaceuticals, which was acquired in 2003 by Hybrigenics. In addition, he was a member of the management team of the Cancer Genomics Center, a center of excellence of the Netherlands Genomics Initiative.

Florent Gros

Mr. Florent Gros is Member of the Supervisory Board of Merus BV. He graduated from Ecole Superieure de Biotechnologie de Strasbourg. He has been a member of the Board since January 2010. He is a Managing Director at Novartis Venture Funds. During the past 20 years, he held various positions in the intellectual property and venture areas at Nestle, Aventis-Pasteur and Novartis, in Switzerland, France and the USA. He holds a French Biotechnology Engineering Master Degree. He holds another Master in Private Law, European and French patent attorney certifications, as well as the Kauffman Fellow venture degree (class 12). He serves on the board of various European and Israeli startup companies.

Elaine Jones

Ms. Elaine V. Jones is Member of the Supervisory Board of Merus BV. She graduated from University of Pittsburgh with a PhD in Microbiology and from Juniata College with a BSc degree in Biology. She has been an observer on the Board since January 2010. She is Executive Director of Pfizer Venture Investments (PVI), responsible for making and managing venture investments for Pfizer. She has held positions as Director of Scientific Licensing for SmithKline Beecham and has managed investments at SR One, GlaxoSmithKline’s corporate venture fund. Before joining PVI, she was a General Partner with the venture fund EuclidSR Partners.

Mark Krul

Mr. Mark Krul is Member of the Supervisory Board of Merus BV. He has been a member of the Board since January 2010. He is a member of the executive management team of Aglaia Biomedical Ventures in Bilthoven, The Netherlands. He has a background in molecular biology and immunology and over 12 years of experience in anticancer drug development. Before founding Aglaia in 2004, he was Program Director of the NDDO Research Foundation. He has headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection. He received his Ph.D. from the University of Utrecht, The Netherlands.